文献速递心力衰竭与心肌病冠心病心律失常

新诊断非缺血性或缺血性心肌病患者穿戴式除颤器评估的心脏性猝死:德国全国SCD-PROTECT研究

Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study.
PubMed 文献 · Eur Heart J · 2025-01-01

NICM与MI/CAD患者首次适当治疗发生率分别为6.10与8.64例/100患者年,多数患者LVEF可改善至>35%。

要点

  • 新诊断低LVEF心肌病患者在药物治疗优化早期VT/VF所致SCA风险较高。
  • NICM患者首次适当WCD治疗发生率6.10/100患者年,MI/CAD为8.64/100患者年。
  • 多数患者LVEF可改善至>35%,可作为两种病因的风险分层依据。

核心结论

  • 新诊断低LVEF患者无论缺血或非缺血病因,在指南推荐药物治疗优化早期VT/VF所致SCA风险均较高,WCD提供SCD保护,LVEF改善至>35%可用于风险分层。

主要发现

  • NICM患者平均年龄58.6±13.7岁,MI/CAD患者64.2±10.6岁;女性分别占23.8%和16.3%。
  • 起始LVEF在NICM为26.9±10.3%,MI/CAD为28.4±8.0%。
  • NICM与MI/CAD首次适当WCD治疗发生率分别为6.10(95%CI 5.31-7.00)与8.64(95%CI 7.41-10.05)例/100患者年。
  • 所有适当治疗发生率密度分别为8.53(95%CI 7.36-9.88)与14.98(95%CI 12.69-17.65)例/100患者年。
  • 平均65.9±43.8天内LVEF改善至>35%者NICM占53.5%、MI/CAD占51.7%;WCD结束时36.2%植入ICD,总死亡率0.8%,不适当电击0.5%。

临床怎么用

  • 对新诊断低LVEF心肌病患者,在药物治疗优化早期可考虑WCD提供SCD保护。
  • LVEF改善至>35%可作为缺血与非缺血病因共同的风险分层指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with newly diagnosed non-ischaemic cardiomyopathy (NICM) or myocardial infarction/coronary artery disease (MI/CAD) face an increased risk of sudden cardiac death (SCD) during the early phase of guideline-recommended medical therapy initiation and up-titration. Aim is to evaluate the risk in this population by assessing sudden cardiac arrest (SCA) due to ventricular tachycardia/ventricular fibrillation (VT/VF). METHODS: All patients in Germany who received a wearable cardioverter-defibrillator (WCD) between December 2021 and May 2023 were enrolled in the observational multicentre SCD-PROTECT study (NCT06883383). The primary outcome was the incidence of SCA due to sustained VT/VF, measured by appropriate WCD-delivered treatments, and reported as events per 100 patient-years with 95% confidence intervals (CI). Secondary outcomes included inappropriate WCD treatments, all-cause mortality, adverse events, adherence to WCD use, and heart failure medication patterns. RESULTS: In this cohort of 19 598 patients, the mean age (±standard deviation) was 58.6 ± 13.7 years for those with NICM and 64.2 ± 10.6 years for patients with MI/CAD. Female patients accounted for 23.8% of the NICM and 16.3% of the MI/CAD group. Left ventricular ejection fraction (LVEF) at study start was 26.9 ± 10.3% for NICM and 28.4 ± 8.0% for MI/CAD patients. The incidence rate of first appropriate treatment by WCD in NICM patients and MI/CAD patients was 6.10 (95% CI 5.31-7.00) and 8.64 (95% CI 7.41-10.05) events per 100 patient-years, respectively. Overall incidence density for all appropriate treatments was 8.53 (95% CI 7.36-9.88) and 14.98 (95% CI 12.69-17.65) per 100 patient-years in the respective groups. Improvement in LVEF to >35% was observed in 53.5% of NICM patients and 51.7% of MI/CAD patients over a mean of 65.9 ± 43.8 days. 36.2% of patients were implanted with a cardioverter-defibrillator at the end of WCD use. Total mortality was 0.8%. Inappropriate shocks occurred in 0.5% of patients. CONCLUSIONS: The SCD-PROTECT study highlights a substantial risk of SCA due to VT/VF during the early phase of guideline-recommended medical therapy optimization in patients with newly diagnosed reduced LVEF, regardless of ischaemic or non-ischaemic origin. The WCD provided SCD protection, the LVEF could improve to >35% in the majority of these patients and can therefore serve as risk stratification across both aetiologies.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Duncker D, Marijon E, Metra M, et al. Sudden cardiac death in newly diagnosed non-ischaemic or ischaemic cardiomyopathy assessed with a wearable cardioverter-defibrillator: the German nationwide SCD-PROTECT study. Eur Heart J. 2025. PMID: 40879135. doi:10.1093/eurheartj/ehaf668

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。